Schering-Plough Corporation
http://www.schering-plough.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Schering-Plough Corporation
Stock Watch: Pfizer’s Q2 Windows Into Wider 2024 Issues
One company’s weak quarterly sales should not make a pharmaceutical winter. But combine the lower sales of major vaccine families across three companies’ portfolios with weak demand in China and it starts to feel chilly.
Ad/Promo Enforcement: US FDA Calls Penalty On Kaleo Auvi-Q Social Media Post By NFL Star’s Wife
An instagram post by Brittany Mahomes, wife of Kansas City Chiefs quarterback Patrick Mahomes, failed to contain any risk information for the epinephrine injector, the FDA’s Office of Prescription Drug Promotion said in an untitled letter.
Quality Issues Star In US FDA Complete Response Letter Trio
Rocket Pharmaceuticals’ gene therapy Kresladi, Daiichi Sankyo/Merck’s patritumab deruxtecan, and AbbVie’s foscarbidopa/foslevodopa (ABBV-951) received CRLs because of manufacturing concerns.
Scholar Rock And Biohaven Get Ready To Flex Their Muscles In SMA
The companies are set to present Phase III results from their rival myostatin inhibitor drugs for spinal muscular atrophy in Q4, while also fast-tracking the candidates in obesity studies.
Company Information
- Other Names / Subsidiaries
-
- Integrated Therapeutics Group
- Nobilon International BV
- Organon BioSciences
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice